bims-lypmec Biomed News
on Lysosomal positioning and metabolism in cardiomyocytes
Issue of 2025–05–04
six papers selected by
Satoru Kobayashi, New York Institute of Technology



  1. Cell. 2025 Apr 24. pii: S0092-8674(25)00406-4. [Epub ahead of print]
      Lysosomes maintain an acidic pH of 4.5-5.0, optimal for macromolecular degradation. Whereas proton influx is produced by a V-type H+ ATPase, proton efflux is mediated by a fast H+ leak through TMEM175 channels, as well as an unidentified slow pathway. A candidate screen on an orphan lysosome membrane protein (OLMP) library enabled us to discover that SLC7A11, the protein target of the ferroptosis-inducing compound erastin, mediates a slow lysosomal H+ leak through downward flux of cystine and glutamate, two H+ equivalents with uniquely large but opposite concentration gradients across lysosomal membranes. SLC7A11 deficiency or inhibition caused lysosomal over-acidification, reduced degradation, accumulation of storage materials, and ferroptosis, as well as facilitated α-synuclein aggregation in neurons. Correction of abnormal lysosomal acidity restored lysosome homeostasis and prevented ferroptosis. These studies have revealed an unconventional H+ transport conduit that is integral to lysosomal flux of protonatable metabolites to regulate lysosome function, ferroptosis, and Parkinson's disease (PD) pathology.
    Keywords:  acidification; cystine; ferroptosis; lysosome; pH optimum
    DOI:  https://doi.org/10.1016/j.cell.2025.04.004
  2. Biomolecules. 2025 Apr 03. pii: 525. [Epub ahead of print]15(4):
      The vacuolar-type ATPase (V-ATPase) is a multi-subunit enzyme complex that maintains lysosomal acidification, a critical process for cellular homeostasis. By controlling the pH within lysosomes, V-ATPase contributes to overall cellular homeostasis, helping to maintain a balance between the degradation and synthesis of cellular components. Dysfunction of V-ATPase impairs lysosomal acidification, leading to the accumulation of undigested materials and contributing to various diseases, including cardiovascular diseases (CVDs) like atherosclerosis and myocardial disease. Furthermore, V-ATPase's role in lysosomal function suggests potential therapeutic strategies targeting this enzyme complex to mitigate cardiovascular disease progression. Understanding the mechanisms by which V-ATPase influences cardiovascular pathology is essential for developing novel treatments aimed at improving outcomes in patients with heart and vascular diseases.
    Keywords:  cardiovascular disease; lysosomal acidification; vacuolar-type ATPase
    DOI:  https://doi.org/10.3390/biom15040525
  3. JACS Au. 2025 Apr 28. 5(4): 2004-2014
      Lysosomes are dynamic, membrane-bound organelles that play key roles in cellular waste disposal, macromolecule recycling, and signaling. Disruptions in lysosomal function and lipid composition are implicated in a wide range of diseases including lysosomal storage disorders, fatty liver disease, atherosclerosis, and cancer. Imaging of the lysosomal lipid composition has the potential to not only enhance the understanding of lysosome-related diseases and their progression but also help identify them. In this work, we present a novel viscosity-sensitive, green-emitting BODIPY probe that can distinguish between ordered and disordered lipid phases and selectively internalize into the lysosomal membranes of live cells. Through the use of fluorescence lifetime imaging microscopy, we demonstrate that lysosomal membranes in multiple cancer cells exhibit significantly higher microviscosities compared to noncancer cells. The differences in lysosomal microviscosities provide an effective approach for identifying cancer cells and indicate that malignant cells may possess more oxidized and saturated lysosomal lipid membranes. Furthermore, we demonstrate the utility of viscosity-sensitive probes in quantifying the compositional changes in lysosomal membranes by investigating the effects of lysosome-permeabilizing cationic amphiphilic drugs (CADs), sertraline, and astemizole. Our results reveal that despite their functional similarities, these CADs exert opposite effects on lysosomal microviscosities in both cancerous and noncancerous cells, suggesting that different mechanisms may contribute to the CAD-induced lysosomal damage and leakage.
    DOI:  https://doi.org/10.1021/jacsau.5c00253
  4. Cell Signal. 2025 Apr 23. pii: S0898-6568(25)00247-5. [Epub ahead of print]132 111834
      Cisplatin is a widely used chemotherapeutic agent in the treatment of non-small cell lung cancer (NSCLC), but cisplatin resistance remains a significant clinical challenge. Lysosomal transmembrane protein 5 (LAPTM5) is a lysosomal membrane protein implicated in macroautophagy/autophagy, although its precise mechanism has yet to be fully elucidated.In this study, we demonstrated that LAPTM5 promotes cisplatin resistance in NSCLC by maintaining lysosomal membrane stability and preserving autophagic flux. Mechanistic investigations showed that LAPTM5 competes with LAMP1 for binding to WWP2, thereby inhibiting LAMP1 ubiquitination and degradation, which ultimately preserves lysosomal membrane stability. LAPTM5 knockdown increases lysosomal membrane permeability, leading to the release of cathepsin D (CTSD), which elevates intracellular reactive oxygen species (ROS) levels; further destabilizing the lysosomal membrane and accelerating cell death. Our findings elucidate the mechanism by which LAPTM5 contributes to cisplatin resistance through lysosomal membrane stabilization and identify LAPTM5 as a potential therapeutic target for overcoming cisplatin resistance in NSCLC.
    Keywords:  Autophagy; Cisplatin; LAMP1; LAPTM5; Lysosomal membrane permeabilization; ROS
    DOI:  https://doi.org/10.1016/j.cellsig.2025.111834
  5. JACC Basic Transl Sci. 2025 Apr;pii: S2452-302X(24)00434-0. [Epub ahead of print]10(4): 475-497
      Heart failure with preserved ejection fraction (HFpEF) is a leading cause of hospitalization and mortality in older adults, yet the role of aging in its pathogenesis remains unclear. Old male mice subjected to chronic metabolic and hypertensive stress (2-hit) developed a more severe HFpEF phenotype compared with young counterparts. We identified that age-related disruptions in protein quality control (PQC) worsens proteostatic stress in HFpEF. Mammalian target of rapamycin complex 1 (mTORC1), a key regulator of PQC, is activated by both aging and 2-hit stress, and cardiac-specific mTORC1 inhibition protects against HFpEF. Our findings highlight the need to integrate aging into preclinical models of HFpEF and suggest targeting PQC as a therapeutic strategy.
    Keywords:  HFpEF; autophagy; cardiac aging; mTORC1; protein degradation; protein quality control; protein synthesis; proteostasis
    DOI:  https://doi.org/10.1016/j.jacbts.2024.11.006
  6. Eur Cardiol. 2025 ;20 e09
      Patients with diabetes are at an increased risk of cardiovascular disease (CVD), including atherosclerotic CVD and heart failure. In addition, diabetes is associated with a higher risk of developing chronic kidney disease, which is considered to be one of the strongest risk factors for CVD and mortality. To address the increased cardiovascular risk of patients with diabetes, dedicated screening strategies for CVD are necessary; conversely, screening for diabetes needs to be performed in all patients with CVD to allow timely identification. Once diabetes is diagnosed, rapid implementation of treatment with therapies to reduce cardiovascular risk on top of standard of care is necessary. This review gives an overview of contemporary therapeutic strategies to reduce cardiovascular risk in patients with type 2 diabetes.
    Keywords:  Diabetes; cardiovascular risk reduction; chronic kidney disease; heart failure
    DOI:  https://doi.org/10.15420/ecr.2024.29